Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bosque

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Blood|April 22, 2006
A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndromeManuel Del-Rey, Jesus Ruiz-Contreras, Alberto Bosque, et al.
AIDS Research and Human Retroviruses|June 22, 2018
Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic VirusAmanda B Macedo, Rachel S Resop, Laura J Martins, et al.
Journal of Virology|February 26, 2016
HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing AssaySara Sunshine, Rory Kirchner, Sami S Amr, et al.
AIDS Research and Human Retroviruses|July 15, 2015
Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent VirusLaura J Martins, Pawel Bonczkowski, Adam M Spivak, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2017
Microbiota promotes systemic T-cell survival through suppression of an apoptotic factorRaymond Soto, Charisse Petersen, Camille L Novis, et al.
Virology|January 26, 2015
Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm VprAna Beatriz DePaula-Silva, Patrick A Cassiday, Jeffrey Chumley, et al.
Antimicrobial Agents and Chemotherapy|June 3, 2020
Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing AgentsEric S Sorensen, Amanda B Macedo, Rachel S Resop, et al.
JCI Insight|October 5, 2018
Dual TLR2 and TLR7 agonists as HIV latency-reversing agentsAmanda B Macedo, Camille L Novis, Caroline M De Assis, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Glucose-Fueled Histone Modifications Drive HIV-1 Latency Reversal at HypoxiaYetunde I Kayode, Deanna C Clemmer, Adebola A Owolabi, et al.
JCI Insight|August 8, 2024
The HIV latency reversing agent HODHBt inhibits the phosphatases PTPN1 and PTPN2J Natalie Howard, Thomas D Zaikos, Callie Levinger, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Blood|April 22, 2006
A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndromeManuel Del-Rey, Jesus Ruiz-Contreras, Alberto Bosque, et al.
AIDS Research and Human Retroviruses|June 22, 2018
Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic VirusAmanda B Macedo, Rachel S Resop, Laura J Martins, et al.
Journal of Virology|February 26, 2016
HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing AssaySara Sunshine, Rory Kirchner, Sami S Amr, et al.
AIDS Research and Human Retroviruses|July 15, 2015
Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent VirusLaura J Martins, Pawel Bonczkowski, Adam M Spivak, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2017
Microbiota promotes systemic T-cell survival through suppression of an apoptotic factorRaymond Soto, Charisse Petersen, Camille L Novis, et al.
Virology|January 26, 2015
Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm VprAna Beatriz DePaula-Silva, Patrick A Cassiday, Jeffrey Chumley, et al.
Antimicrobial Agents and Chemotherapy|June 3, 2020
Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing AgentsEric S Sorensen, Amanda B Macedo, Rachel S Resop, et al.
JCI Insight|October 5, 2018
Dual TLR2 and TLR7 agonists as HIV latency-reversing agentsAmanda B Macedo, Camille L Novis, Caroline M De Assis, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Glucose-Fueled Histone Modifications Drive HIV-1 Latency Reversal at HypoxiaYetunde I Kayode, Deanna C Clemmer, Adebola A Owolabi, et al.
JCI Insight|August 8, 2024
The HIV latency reversing agent HODHBt inhibits the phosphatases PTPN1 and PTPN2J Natalie Howard, Thomas D Zaikos, Callie Levinger, et al.
Pageof 9